PMID- 19831841
OWN - NLM
STAT- MEDLINE
DCOM- 20091223
LR  - 20211020
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Print)
IS  - 1473-7175 (Linking)
VI  - 9
IP  - 10
DP  - 2009 Oct
TI  - Convection-enhanced delivery for the treatment of brain tumors.
PG  - 1519-27
LID - 10.1586/ern.09.99 [doi]
AB  - The brain is highly accessible for nutrients and oxygen, however delivery of 
      drugs to malignant brain tumors is a very challenging task. Convection-enhanced 
      delivery (CED) has been designed to overcome some of the difficulties so that 
      pharmacological agents that would not normally cross the BBB can be used for 
      treatment. Drugs are delivered through one to several catheters placed 
      stereotactically directly within the tumor mass or around the tumor or the 
      resection cavity. Several classes of drugs are amenable to this technology 
      including standard chemotherapeutics or novel experimental targeted drugs. The 
      first Phase III trial for CED-delivered, molecularly targeted cytotoxin in the 
      treatment of recurrent glioblastoma multiforme has been accomplished and 
      demonstrated objective clinical efficacy. The lessons learned from more than a 
      decade of attempts at exploiting CED for brain cancer treatment weigh critically 
      for its future clinical applications. The main issues center around the type of 
      catheters used, number of catheters and their exact placement; pharmacological 
      formulation of drugs, prescreening patients undergoing treatment and monitoring 
      the distribution of drugs in tumors and the tumor-infiltrated brain. It is 
      expected that optimizing CED will make this technology a permanent addition to 
      clinical management of brain malignancies.
FAU - Debinski, Waldemar
AU  - Debinski W
AD  - Brain Tumor Center of Excellence, Comprehensive Cancer Center of Wake Forest 
      University, Department of Neurosurgery, Wake Forest University School of 
      Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. 
      debinski@wfubmc.edu
FAU - Tatter, Stephen B
AU  - Tatter SB
LA  - eng
GR  - R01 CA074145/CA/NCI NIH HHS/United States
GR  - R01 CA139099/CA/NCI NIH HHS/United States
GR  - R01 CA 74145/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Anticonvulsants/*administration & dosage
MH  - Brain Neoplasms/*therapy
MH  - Catheters, Indwelling
MH  - *Convection
MH  - *Drug Delivery Systems/methods
MH  - Humans
PMC - PMC3657605
MID - NIHMS155089
EDAT- 2009/10/17 06:00
MHDA- 2009/12/24 06:00
PMCR- 2013/05/19
CRDT- 2009/10/17 06:00
PHST- 2009/10/17 06:00 [entrez]
PHST- 2009/10/17 06:00 [pubmed]
PHST- 2009/12/24 06:00 [medline]
PHST- 2013/05/19 00:00 [pmc-release]
AID - 10.1586/ern.09.99 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2009 Oct;9(10):1519-27. doi: 10.1586/ern.09.99.